Pluri Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Pluri Inc. (PLUR) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$1.55 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-09-10
- Pluri Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$313.00K.
- Pluri Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$624.00K.
- Pluri Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$329.00K.
- Pluri Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$282.00K.
- Pluri Inc. net income (loss) attributable to noncontrolling interest for fiscal 2026 was -$1.55M.
- Pluri Inc. net income (loss) attributable to noncontrolling interest for fiscal 2025 was -$667.00K.
- Pluri Inc. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$456.00K.
- Pluri Inc. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$566.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | -$937.00K derived: sum of 2 quarters · filed 2026-09-10 | -$1.27M derived: sum of 3 quarters · filed 2026-09-10 | -$1.55M 10-K · filed 2026-09-10 |
| 2026-03-31 | -$624.00K 10-Q · filed 2026-05-14 | -$953.00K derived: sum of 2 quarters · filed 2026-05-14 | -$1.24M 10-Q · filed 2026-05-14 | -$1.41M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-12-31 | -$329.00K 10-Q · filed 2026-02-12 | -$611.00K 10-Q · filed 2026-02-12 | -$782.00K derived: sum of 3 quarters · filed 2026-09-10 | -$970.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-09-30 | -$282.00K 10-Q · filed 2025-11-12 | -$453.00K derived: sum of 2 quarters · filed 2026-09-10 | -$641.00K derived: sum of 3 quarters · filed 2026-09-10 | -$795.00K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-06-30 | -$171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | -$359.00K derived: sum of 2 quarters · filed 2026-09-10 | -$513.00K derived: sum of 3 quarters · filed 2026-09-10 | -$667.00K 10-K · filed 2026-09-10 |
| 2025-03-31 | -$188.00K 10-Q · filed 2026-05-14 | -$342.00K derived: sum of 2 quarters · filed 2026-05-14 | -$496.00K 10-Q · filed 2026-05-14 | -$629.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$154.00K 10-Q · filed 2026-02-12 | -$308.00K 10-Q · filed 2026-02-12 | -$441.00K derived: sum of 3 quarters · filed 2026-02-12 | -$538.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | -$154.00K 10-Q · filed 2025-11-12 | -$287.00K derived: sum of 2 quarters · filed 2025-11-12 | -$384.00K derived: sum of 3 quarters · filed 2025-11-12 | -$473.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-17 | -$230.00K derived: sum of 2 quarters · filed 2025-09-17 | -$319.00K derived: sum of 3 quarters · filed 2025-09-17 | -$456.00K 10-K · filed 2025-09-17 |
| 2024-03-31 | -$97.00K 10-Q · filed 2025-05-13 | -$186.00K derived: sum of 2 quarters · filed 2025-05-13 | -$323.00K 10-Q · filed 2025-05-13 | -$470.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$89.00K 10-Q · filed 2025-02-11 | -$226.00K 10-Q · filed 2025-02-11 | -$373.00K derived: sum of 3 quarters · filed 2025-02-11 | -$507.00K derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-09-30 | -$137.00K 10-Q · filed 2024-11-12 | -$284.00K derived: sum of 2 quarters · filed 2024-11-12 | -$418.00K derived: sum of 3 quarters · filed 2024-11-12 | -$555.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | -$281.00K derived: sum of 2 quarters · filed 2024-09-18 | -$418.00K derived: sum of 3 quarters · filed 2024-09-18 | -$566.00K 10-K · filed 2024-09-18 |
| 2023-03-31 | -$134.00K 10-Q · filed 2024-05-09 | -$271.00K derived: sum of 2 quarters · filed 2024-05-09 | -$419.00K 10-Q · filed 2024-05-09 | -$498.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$137.00K 10-Q · filed 2024-02-12 | -$285.00K 10-Q · filed 2024-02-12 | -$364.00K derived: sum of 3 quarters · filed 2024-02-12 | -$417.00K derived: sum of 4 quarters · filed 2024-02-12 |
| 2022-09-30 | -$148.00K 10-Q · filed 2023-11-13 | -$227.00K derived: sum of 2 quarters · filed 2023-11-13 | -$280.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | -$132.00K derived: sum of 2 quarters · filed 2023-09-12 | -$132.00K 10-K · filed 2023-09-12 | |
| 2022-03-31 | -$53.00K 10-Q · filed 2023-05-09 | -$53.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |